Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Jun;69(3):268–285. doi: 10.1016/j.curtheres.2008.06.005

The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: A review

Paul Gavaza 1, Karen Rascati 1,a, Carolyn Brown 1, Kenneth Lawson 1, Teresa Mann 1
PMCID: PMC3969967  PMID: 24692805

Abstract

BACKGROUND: Economic evaluation of health care has developed into a substantial body of work, and its contribution to medical decision making is increasingly being recognized.

OBJECTIVE: The aim of the study was to describe the characteristics and quality of health economic (including pharmacoeconomic) evaluation research studies related to Zimbabwe.

METHODS: A review of the literature was conducted to identify published health economic evaluation studies related to Zimbabwe. HEED, PubMed, MEDLINE, HealthSTAR, EconLit, and PsycINFO databases and sociological and dissertation abstracts were used to search for economic analyses. The searches used the following terms alone and in combination: costs, budgets, fee, economics, health, pharmacy, pharmacy services, medicines, drugs, health economics, cost-effectiveness, cost-benefit, cost-minimization, cost utility analysis, and Zimbabwe. Only original applied economic evaluations addressing a health-related topic pertaining to Zimbabwe and published in full were included. Two reviewers independently evaluated and scored each study in the final sample using the data collection form designed for the study.

RESULTS: Fifty-nine studies were identified in the database searches, 18 of which were excluded because they were not about Zimbabwe (3 studies) or were not health related (15). Of the 41 remaining studies, 8 were excluded after further review because they were not original research, 6 because they were not economic analyses, and 1 because it was not about Zimbabwe. The final 26 studies appeared in 13 different journals (based mostly [17 (65%)] outside of Zimbabwe). The mean (SD) number of authors of each study was 3.36 (2.13); most of the authors had medical/clinical training. The number of studies peaked between 1994 and 1997. Based on a 10-point scale, with 10 indicating the highest quality, the mean (SD) quality score for all studies was 5.40 (1.56); 8 of the studies (31%) were considered to be of poor quality (score ≤4). The quality of the studies reviewed was significantly (all, P < 0.05) associated with the country in which the journal was based (non-Zimbabwe = higher), the primary health intervention (services>pharmaceutical interventions), the number of authors (more authors = higher), and year of publication (more recent = higher).

CONCLUSION: This study indicated that the use of health economic (including pharmacoeconomic) evaluation research in Zimbabwe was low, and 31 % of the studies were of poor quality. More and better quality health economic research in Zimbabwe is warranted.

Keywords: cost-effective analysis, health economics, pharmacoeconomics, economic evaluation, quality assessment, Zimbabwe

Full Text

The Full Text of this article is available as a PDF (997.2 KB).

References

  • 1.Drummond MF, Sculpher MJ, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford University Press; Oxford, UK: 2005. [Google Scholar]
  • 2.Gerard K. Cost-utility in practice: A policy maker's guide to the state of the art. Health Policy. 1992;21:249–279. doi: 10.1016/0168-8510(92)90022-4. [DOI] [PubMed] [Google Scholar]
  • 3.Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med. 1992;116:238–244. doi: 10.7326/0003-4819-116-3-238. [DOI] [PubMed] [Google Scholar]
  • 4.Adams ME, McCall NT, Gray DT. Economic analysis in randomized control trials. Med Care. 1992;30:231–243. doi: 10.1097/00005650-199203000-00005. [DOI] [PubMed] [Google Scholar]
  • 5.Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: A review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000;283:2116–2121. doi: 10.1001/jama.283.16.2116. [DOI] [PubMed] [Google Scholar]
  • 6.Colmenero F, Sullivan SD, Palmer JA. Quality of clinical and economic evidence in dossier formulary submissions. Am J Manag Care. 2007;13:401–407. [PubMed] [Google Scholar]
  • 7.Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: A critical review of the published literature. Health Econ. 2000;9:681–698. doi: 10.1002/1099-1050(200012)9:8<681::aid-hec545>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 8.Lee KS, Brouwer WB, Lee SI, Koo HW. Introducing economic evaluation as a policy tool in Korea: Will decision makers get quality information? A critical review of published Korean economic evaluations. PharmacoEconomics. 2005;23:709–721. doi: 10.2165/00019053-200523070-00005. [DOI] [PubMed] [Google Scholar]
  • 9.Robinson S. A tale of two countries. 2002 http://www.time.com/time/printout/0,8816,203620,00.html Monday, February 18. Accessed May 24, 2008. [Google Scholar]
  • 10.Hansen K, Chapman G, Chitsike I. The costs of HIV/AIDS care at government hospitals in Zimbabwe. Health Policy Plan. 2000;15:432–440. doi: 10.1093/heapol/15.4.432. [DOI] [PubMed] [Google Scholar]
  • 11.Zimbabwe: Demographic and health survey, 2005–2006. Preliminary report. Central Statistical Office and ORC Macro; Harare, Zimbabwe: 2006. [Google Scholar]
  • 12.Bvochora JF, Kasilo OJ, Nhachi CF. Disease pattern and prescribing at the University of Zimbabwe students health service, 1987–1991. Cent Afr J Med. 1993;39:88–95. [PubMed] [Google Scholar]
  • 13.Hore R. AIDS and private health costs in Zimbabwe. SAfAIDS News. 1997;5:2–6. [PubMed] [Google Scholar]
  • 14.Hore R. Zimbabwe: Are the costs of AIDS medical care affordable? AIDS Anal Afr. 1993;3:6–8. [PubMed] [Google Scholar]
  • 15.Mitchell MD, Littlefield J, Gutter S. Costing of reproductive health services. Int Fam Plan Perspect. Int Fam Plan Perspect. 1999;1999;2525:S17–S21. S29. [Google Scholar]
  • 16.Drummond MF, Stoddart GL. Torrance GW Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press; Oxford, UK: 1987. [Google Scholar]
  • 17.Sullivan SD, Lyles A, Luce BR, Grigar J. AMCP Guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. J Manag Care Pharm. 2001;7:272–282. [Google Scholar]
  • 18.Zarnke K, Levine M, O'Brien B. Cost-benefit analysis in the health care literature: Don't judge a study by its label. J Clin Epidemiol. 1997;50:817–822. doi: 10.1016/s0895-4356(97)00064-4. [DOI] [PubMed] [Google Scholar]
  • 19.Offman J, Sullivan S, Neumann P. Examining the value and quality of health economic analyses: Implications of utilizing the QHES. J Manag Care Pharm. 2003;9:53–61. doi: 10.18553/jmcp.2003.9.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Chisadza E, Maponga CC, Nazerali H. User fees and drug pricing policies: A study at Harare Central Hospital, Zimbabwe. Health Policy Plan. 1995;10:319–326. doi: 10.1093/heapol/10.3.319. [DOI] [PubMed] [Google Scholar]
  • 21.Gomo E, Ndamba J, Murahwa S. In vitro activity of several antimicrobial agents against Neisseria gonorrhoeae and comparison of cost of treatment. Cent Afr J Med. 1995;41:83–86. [PubMed] [Google Scholar]
  • 22.Hansen K, Woelk G, Jackson H. The cost of home-based care for HIV/AIDS patients in Zimbabwe. AIDS Care. 1998;10:751–759. doi: 10.1080/09540129848361. [DOI] [PubMed] [Google Scholar]
  • 23.Harvey PD. The impact of condom prices on sales in social marketing programs. Stud Fam Plan. 1994;25:52–58. [PubMed] [Google Scholar]
  • 24.Hongoro C, McPake B. Hospital costs of high-burden diseases: Malaria and pulmonary tuberculosis in a high HIV prevalence context in Zimbabwe. Trop Med Int Health. 2003;8:242–250. doi: 10.1046/j.1365-3156.2003.01014.x. [DOI] [PubMed] [Google Scholar]
  • 25.Hore R. The impact of AIDS on direct health care costs in Zimbabwe. AIDS Anal Afr. 1997;7:8–9. [PubMed] [Google Scholar]
  • 26.Kravitz J, Sanders D. Paediatric pneumonia in Zimbabwe: Management and pharmaceutical costs of inpatient care. J Trop Pediatr. 1994;40:17–23. doi: 10.1093/tropej/40.1.17. [DOI] [PubMed] [Google Scholar]
  • 27.McFarland W, Kahn JG, Katzenstein DA. Deferral of blood donors with risk factors for HIV infection saves lives and money in Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:183–192. [PubMed] [Google Scholar]
  • 28.McPake B, Hongoro C. Contracting out of clinical services in Zimbabwe. Soc Sci Med. 1995;41:13–24. doi: 10.1016/0277-9536(94)00303-b. [DOI] [PubMed] [Google Scholar]
  • 29.Manyemba J. A randomised crossover comparison of reserpine and sustained-release nifedipine in hypertension. Cent Afr J Med. 1997;43:344–349. [PubMed] [Google Scholar]
  • 30.Palmer DL, Mason PR, Pasi C, Tobiwa O. Value of mandatory testing for human immunodeficiency virus in a sub-Saharan hospital population. Clin Infect Dis. 2000;31:1258–1265. doi: 10.1086/317453. [DOI] [PubMed] [Google Scholar]
  • 31.Ndamba J, Makura O, Gwatirisa PR. A cost effective two step rapid diagnosis of urinary schistosomiasis in Zimbabwe. Cent Afr J Med. 1998;44:167–171. [PubMed] [Google Scholar]
  • 32.Nhachi FB, Kasilo OJ, Mutengezanwa A, Zvandaziva EA. Drug utilisation, supply and expenditure at Chitungwiza, Gweru, Mpilo, Parirenyatwa and United Bulawayo Hospitals in one year (1987–1988) Cent AfrJ Med. 1991;37:159–167. [PubMed] [Google Scholar]
  • 33.Sweat MD, O'Reilly KR, Schmid GP. Cost-effectiveness of nevirapine to prevent motherto-child HIV transmission in eight African countries. AIDS. 2004;18:1661–1671. doi: 10.1097/01.aids.0000131353.06784.8f. [DOI] [PubMed] [Google Scholar]
  • 34.Vander Plaetse B, Hlatiwayo G, Van Eygen L. Costs and revenue of health care in a rural Zimbabwean district. Health Policy Plan. 2005;20:243–251. doi: 10.1093/heapol/czi028. [DOI] [PubMed] [Google Scholar]
  • 35.Vos J, Borgdorff MW, Kachidza EG. Cost and output of mobile clinics in a commercial farming area in Zimbabwe. Soc Sci Med. 1990;31:1207–1211. doi: 10.1016/0277-9536(90)90125-c. [DOI] [PubMed] [Google Scholar]
  • 36.Verkuyl DA. Economics of anti-rhesus prophylaxis in an African population. Cent Afr J Med. 1987;33:32–37. [PubMed] [Google Scholar]
  • 37.Waterkeyn J, Caimcross S. Creating demand for sanitation and hygiene through Community Health Clubs: A cost-effective intervention in two districts in Zimbabwe. Soc Sci Med. 2005;61:1958–1970. doi: 10.1016/j.socscimed.2005.04.012. [DOI] [PubMed] [Google Scholar]
  • 38.Watts R. Low-cost water supplies and their contribution to health. Afr Health. 1992;15:10–11. [PubMed] [Google Scholar]
  • 39.Janowitz B, Johnson L, Thompson A. Excess capacity and the cost of adding services at family planning clinics in Zimbabwe. Int Fam Plan Perspect. 2002;28:58. [Google Scholar]
  • 40.Chishawa O, Ziyambi Z, Ndhlovu P. Comparative evaluation and assessment of the diagnostic usefulness of four commercial HIV-1/HIV-2 antibody assays using two well-characterized serum panels from Blood Transfusion Service and the National Health Laboratory Services in Zimbabwe. Cent Afr J Med. 2001;47:1–8. doi: 10.4314/cajm.v47i1.8583. [DOI] [PubMed] [Google Scholar]
  • 41.Dzvaka SK, Gavaza P, Mukosera KT; Zimbabwe community pharmacists' opinions on continuing education: The case of Harare community pharmacists. East Cent Afr J Pharma Sci. In press.
  • 42.Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: Are the data good enough to be used by policy-makers? PharmacoEconomics. 2007;25:467–479. doi: 10.2165/00019053-200725060-00003. [DOI] [PubMed] [Google Scholar]
  • 43.Maynard A. Developing the health care market. Economics journal. 1991;101:1277–1286. [Google Scholar]
  • 44.Canadian Coordinating Office of Health Technology Assessment (CCOHTA) Guidelines for Economic Evaluation of Pharmaceuticals. 2nd ed. CCOHTA Publications; Ottawa, Ontario, Canada: 1997. [DOI] [PubMed] [Google Scholar]
  • 45.Commonwealth Department of Health HaCS . Guidelines for the Pharmaceutical Industry on Preperation of Submissions to the Pharmaceutical Benefits Advisory Committee. Australian Government Publishing Service; Canberra, Australia: 1995. [Google Scholar]
  • 46.Elixhauser A, Luce B, Taylor W, Reblando J. Health-care CBA/CEA—an update on the growth and composition of the literature. Med Care. 1993;31:JS1–JS11. doi: 10.1097/00005650-199307001-00001. [DOI] [PubMed] [Google Scholar]
  • 47.Hjelmgren J, Berggren F, Andersson F. Health economic guidelines-similarities, differences and some implications. Value Health. 2001;4:225–250. doi: 10.1046/j.1524-4733.2001.43040.x. [DOI] [PubMed] [Google Scholar]
  • 48.Neumann PJ, Stone PW, Chapman RH. The quality of reporting in published cost-utility analyses, 1976–1997. Ann Intern Med. 2000;132:964–972. doi: 10.7326/0003-4819-132-12-200006200-00007. [DOI] [PubMed] [Google Scholar]
  • 49.Gerard K, Smoker I, Seymour J. Raising the quality of cost-utility analyses: Lessons learnt and still to learn. Health Policy. 1999;46:217–238. doi: 10.1016/s0168-8510(98)00061-x. [DOI] [PubMed] [Google Scholar]
  • 50.Garcia-Altes A. Twenty years of health care economic analysis in Spain: Are we doing well? Health Econ. 2001;10:715–729. doi: 10.1002/hec.608. [DOI] [PubMed] [Google Scholar]
  • 51.Bell CM, Urbach DR, Ray JG. Bias in published cost effectiveness studies: Systematic review. BMJ. 2006;332:699–703. doi: 10.1136/bmj.38737.607558.80. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES